abcam

ab250149

Anti-AP3M2 antibody [EPR12965] - BSA and Azide free

Recombinant | RabMAb

Key facts

Isotype	IgG
Host species	Rabbit
Storage buffer	pH: 7.2 - 7.4 Constituents: PBS
Form	Liquid
Clonality	Monoclonal
Immunogen	The exact immunogen used to generate this antibody is proprietary information.
Carrier free	Yes
Clone number	EPR12965
Purification technique	Affinity purification
Concentration	0.983 mg/mL The concentration of this product may be batch-dependent Batch concentration finder →

Reactivity data

ICC/IF

Tested

Species	Human
Dilution info	-

Notes	-

Predicted

Species	Mouse, Rat
Dilution info	-
Notes	-

WB

Tested

Species	Human
Dilution info	-
Notes	-

Predicted

Species	Mouse, Rat
Dilution info	-
Notes	-

Flow Cyt (Intra)

Tested

Species	Human
Dilution info	-
Notes	-

Predicted

Species	Mouse, Rat
Dilution info	-
Notes	-

Target data

See full target information AP3M2

Function	Part of the AP-3 complex, an adaptor-related complex which is not clathrin-associated. The complex is associated with the Golgi region as well as more peripheral structures. It facilitates the budding of vesicles from the Golgi membrane and may be directly involved in trafficking to lysosomes. In concert with the BLOC-1 complex, AP-3 is required to target cargos into vesicles assembled at cell bodies for delivery into neurites and nerve terminals.

Storage

Shipped at conditions	Blue Ice
Appropriate short-term storage conditions	+4°C
Appropriate long-term storage conditions	+4°C
Storage information	Do Not Freeze

Notes

ab250149 is the carrier-free version of ab180138.

Patented technology

Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

What are the advantages of a recombinant monoclonal antibody?

This product is a recombinant monoclonal antibody, which offers several advantages including:

- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production

For more information, read more on recombinant antibodies.

Conjugation ready

Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.

Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.

Compatibility

This product is compatible with the Maxpar® Antibody Labeling Kit from Fluidigm, without the need for antibody

preparation. Maxpar® is a trademark of Fluidigm Canada Inc.

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.

Activity summary	AP3M2 also known as Adapter-Related Protein Complex 3 Mu 2 Subunit is a protein that plays a critical role in intracellular trafficking processes. It has a molecular mass of approximately 50 kDa. This protein is expressed in various tissues and is significantly abundant in the nervous system. AP3M2 forms part of the AP-3 complex which is essential for protein sorting and transport from the trans-Golgi network to endosomes and lysosomes.
Biological function summary	AP3M2 contributes to the regulation of membrane protein localization. It acts as part of the AP-3 complex working together with other subunits to facilitate vesicle formation and cargo selection for transport. The AP-3 complex is an adaptor protein complex that functions in the clathrin-independent transport pathway important for lysosomal protein sorting. AP3M2's function ensures proper cellular compartmentalization and distribution of lysosomal enzymes and membrane proteins.
Pathways	AP3M2 functions in the context of both the endocytic and secretory pathways. Within these pathways the protein partakes alongside proteins like VPS41 and HPS1 contributing to vesicular trafficking and organelle biogenesis. In the endocytic pathway AP3M2 helps in the transport of cargo to lysosomes affecting protein degradation and recycling while in the secretory pathway it assists in packaging lysosomal proteins for delivery to their proper cellular destinations.
Associated diseases and disorders	AP3M2 is linked to Hermansky-Pudlak syndrome and neurodevelopmental disorders. Mutations in the genes encoding proteins of the AP-3 complex including AP3M2 are known to disrupt normal vesicular trafficking leading to symptoms observed in Hermansky-Pudlak syndrome a disorder characterized by albinism and bleeding issues. Furthermore alterations in AP3M2 function are also associated with neurological disorders linking to proteins like BI1 and AP3B1 affecting neuronal migration and synaptic function.

Product promise

Tested

We have tested this species and application combination and it works. It is covered by our product promise.

Expected

We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.

Predicted

This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.

Not recommended

We do not recommend this combination. It is not covered by our product promise.


We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.

In the unlikely event of one of our products not working as expected, you are covered by our product promise.

Full details and terms and conditions can be found here:
Terms & Conditions.

---


4 product images



Flow Cytometry (Intracellular) - Anti-AP3M2 antibody [EPR12965] - BSA and Azide free (ab250149)

AP3M2 Flow Cytometry (Intracellular) staining using rabbit Anti-AP3M2 antibody


This data was developed using ab180138, the same antibody clone in a different buffer formulation.
Intracellular flow cytometric analysis of 2% paraformaldehyde fixed U87-MG cells labeling AP3M2 with ab180138 at 1/30 dilution. Secondary antibody Goat anti rabbit IgG (FITC) at 1/75 dilution. Isotype control Rabbit IgG.



Immunocytochemistry/ Immunofluorescence - Anti-AP3M2 antibody [EPR12965] - BSA and Azide free (ab250149)

AP3M2 Immunocytochemistry/ Immunofluorescence staining using rabbit Anti-AP3M2 antibody

This data was developed using ab180138, the same antibody clone in a different buffer formulation.
Immunofluorescent analysis of 4% paraformaldehyde-fixed HepG2 cells labeling AP3M2 with ab180138 at 1/500 dilution. Secondary antibody Goat anti rabbit IgG(Dylight 488) at 1/250 dilution. Conterstained with Dapi blue.



Western blot - Anti-AP3M2 antibody [EPR12965] - BSA and Azide free (ab250149)

AP3M2 Western blot staining of U87-MG using rabbit Anti-AP3M2 antibody


This data was developed using ab180138, the same antibody clone in a different buffer formulation.
All lanes:
Western blot - Anti-AP3M2 antibody [EPR12965] - N-terminal (ab180138) at 1/5000 dilution

All lanes:
U87-MG at 20 µg

Secondary

All lanes:
Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated at 1/1000 dilution

Predicted band size: 47 kDa



Western blot - Anti-AP3M2 antibody [EPR12965] - BSA and Azide free (ab250149)

AP3M2 Western blot staining using rabbit Anti-AP3M2 antibody

This data was developed using ab180138, the same antibody clone in a different buffer formulation.
All lanes:
Western blot - Anti-AP3M2 antibody [EPR12965] - N-terminal (ab180138) at 1/20000 dilution

Lane 1:
Human fetal brain tissue lysate at 20 µg

Lane 2:
HepG2 cell Lysate at 20 µg

Lane 3:
SH-SY5Y cell Lysate at 20 µg

Secondary

All lanes:
Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated at 1/1000 dilution

Predicted band size: 47 kDa

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.